R.P. Scherer selegiline Zydis wafer NDA to be filed in early 1996, softgel maker tells UBS meeting.
Executive Summary
R.P. SCHERER SELEGILINE ZYDIS NDA SUBMISSION IN EARLY 1996 will be the first "therapeutically-enhanced generic" to be registered at FDA by the company's Advanced Therapeutics Products group, R.P. Scherer Chief Financial Officer Nicole Williams told analysts Oct. 18 in Manhattan at the UBS Securities Life Sciences Conference. Scherer's ATP "will be taking generic drugs, placing them in Scherer drug delivery systems, and taking them through the clinical and regulatory stages to the marketplace," Williams said.